| Table 1. Descriptive analysis of patients’ characteristics, COS outcomes, and oocytes dysmorphisms, for the first ICSI cycle with the GnRH agonist regimen, and the following ICSI cycle with the GnRH antagonist regime | |||
| GnRH Agonist | GnRH Antagonist | p | |
| Maternal age (years) | 35.59±3.39 | 35.97±3.54 | 0.444 |
| Maternal BMI (kg/m2) | 23.27±3.51 | 23.15±3.19 | 0.813 |
| Total FSH dose (IU) | 2532.94±90.76 | 2484.37±90.79 | 0.706 |
| COS outcomes | |||
| Oestradiol peak (pg/ml) | 2232.41±2345.78 | 1731.75±1524.74 | 0.128 |
| Follicles (n) | 14.52±10.53 | 13.89±10.60 | 0.485 |
| Oocytes (n) | 9.87±7.04 | 8.83±6.19 | 0.453 |
| Oocyte Yield (%) | 69.70 | 66.01 | 0.713 |
| Metaphase II oocyte (n) | 7.17±5.53 | 6.77±4.82 | 0.647 |
| Mataphase I oocyte (n) | 1.39±1.77 | 1.03±1.65 | 0.105 |
| Prophase I oocyte (n) | 1.30±1.87 | 1.03±1.78 | 0.757 |
| Mature oocytes rate (%) | 73.82 | 79.3 | 0.342 |
| Oocyte dysmorphisms* | |||
| Granulation cluster (%) | 4.04±14.52 | 5.61±16.91 | 0.483 |
| Dark cytoplasm (%) | 4.40±17.70 | 0.69±3.28 | 0.047 |
| sERC (%) | 7.36±17.17 | 4.37±11.62 | 0.046 |
| Vacuoles (%) | 5.80±15.76 | 6.50±15.00 | 0.746 |
| Perivitelline granules (%) | 45.36±32.31 | 51.24±34.32 | 0.213 |
| Large PVS (%) | 24.08±29.21 | 24.51±29.24 | 0.917 |
| ZP dysmorphism (%) | 11.84±25.13 | 6.05±14.76 | 0.049 |
| PB fragmentation (%) | 33.10±26.30 | 32.30±27.75 | 0.677 |
| Controlled for the presence of other oocyte dysmorphisms.Note: COS—controlled ovarian stimulation; BMI—body mass index; FSH—follicle-stimulating hormone; IU—international unit; sERC—smooth endoplasmic reticulum cluster; PVS—perivitelline space; ZP—zona pellucida; PB—polar body. | |||